the importance of targeting other pathways after jaki treatment failure
Published 1 year ago • 27 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
2:08
an insight into the current understanding of risk factors for cll
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
1:01
recent and future changes in the landscape of aml: the addition of venetoclax and mrd eradication
-
3:39
applications of ai in hemonc: improving diagnosis & predicting outcomes and response to therapy
-
2:04
the importance of patient perspectives during treatment journeys
-
1:06
isth 2024 highlights: promising upcoming treatments for hemophilia
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
30:20
removing analytical bottlenecks in cell therapy [webinar]
-
6:24
indiko biochemistry analyzer demonstration
-
7:25
ai in hematology: advances, challenges, and future applications
-
2:56
novel drugs for myeloma thromboprophylaxis
-
1:00
isct 2020: looking forward to advances and emerging technologies in immune-mediated cancer therapy
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
1:55
donor type and source of choice
-
1:52
targeting the lectin pathway in hsct-tma
-
3:17
pet imaging to predict treatment outcomes: follow-up from the echelon-2 trial
-
2:20
ultra high-risk myeloma
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
2:09
heart transplantation in attr amyloidosis
-
2:08
looking forward to the texas mpn workshop 2020
-
4:07
hd17: pet guided omission of radiotherapy in hodgkin lymphoma